Dasatinib overrides the differentiation blockage in a patient with mutant- KIT  D816V positive CBF&#x03B2;-MYH11 leukemia

Kerstin M. Kampa-Schittenhelm; Wichard Vogel; Irina Bonzheim; Falko Fend; Marius Horger; Lothar Kanz; Martin Soekler; Marcus M. Schittenhelm

doi:10.18632/oncotarget.24376

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Case Reports:

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia

Kerstin M. Kampa-Schittenhelm, Wichard Vogel, Irina Bonzheim, Falko Fend, Marius Horger, Lothar Kanz, Martin Soekler and Marcus M. Schittenhelm _

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2018; 9:11876-11882. https://doi.org/10.18632/oncotarget.24376

Metrics: PDF 1338 views | HTML 2430 views | ?

Abstract

Kerstin M. Kampa-Schittenhelm1, Wichard Vogel1, Irina Bonzheim2, Falko Fend2, Marius Horger3, Lothar Kanz1, Martin Soekler1 and Marcus M. Schittenhelm1

1Department of Oncology, Hematology, Rheumatology, Clinical Immunology and Pulmonology, University Hospital Tübingen, Tübingen, Germany

2Institute of Pathology and Neuropathology, Reference Center for Hematopathology, University Hospital Tübingen, Tübingen, Germany

3Department of Diagnostic and Interventional Radiology, University Hospital Tübingen, Tübingen, Germany

Correspondence to:

Marcus M. Schittenhelm, email: [email protected]

Keywords: CBF AML; KIT; tyrosine kinase inhibition; differentiation

Received: September 18, 2017 Accepted: January 15, 2018 Published: January 31, 2018

ABSTRACT

Activating KIT D816V mutations are frequently found in CBF AML, which predicts for an unfavorable outcome. Dasatinib is a potent inhibitor of wildtype and mutant-KIT isoforms – including D816V. We now provide proof of antileukemic efficacy in a patient with relapsing mutant-KIT D816V CBF AML. Importantly, this effect is mediated via overriding the differentiation blockage of the leukemia clone.

In addition, we show that dasatinib is capable to induce pulmonary differentiation syndrome – and therefore needs close monitoring of patients under therapy.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 24376

Publication Alerts

Case Reports:

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia

Abstract